Early recurrence, time‐to‐recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M‐HNSCC) patients treated with first line platinum‐based chemotherapy

Early recurrence, time‐to‐recurrence, and recurrence patterns: Assessing their impact on survival outcomes in head and neck squamous cell carcinoma (R/M‐HNSCC) patients treated with first line platinum‐based chemotherapy

Background R/M‐HNSCC patients typically receive 1L platinum‐based chemotherapy with pembrolizumab or cetuximab. However, the outcomes for patients with early recurrence (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer medicine (Malden, MA) MA), 2024-02, Vol.13 (4), p.e7047-n/a
Hauptverfasser: Pitakpaiboonkul, Pasvich, Jiarpinitnun, Chuleeporn, Pattaranutaporn, Poompis, Ngamphaiboon, Nuttapong
Format: Artikel
Sprache:eng
Schlagworte:
Cancer therapies
Chemotherapy
Clinical trials
early recurrent head and neck squamous cell carcinoma
Head & neck cancer
Head and neck carcinoma
Histology
Immunotherapy
Medical prognosis
Medical records
Metastases
Metastasis
Multivariate analysis
Pathology
Patients
pattern of recurrence
Pembrolizumab
Platinum
Prognosis
R/M‐HNSCC
Radiation therapy
recurrent/metastatic head and neck squamous cell carcinoma
Squamous cell carcinoma
Surgery
time to recurrence
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background R/M‐HNSCC patients typically receive 1L platinum‐based chemotherapy with pembrolizumab or cetuximab. However, the outcomes for patients with early recurrence (
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.7047